Does COVID-19 increase the risk of neuropsychiatric sequelae? Evidence from a mendelian randomization approach

doi:10.5498/wjp.v12.i3.536

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4820)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

285

WORD

HTML

2785

Figures (1-1)

149

Tables (1-1)

132

Sum=3449

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

193

Download

370

Sum=563

Publishing Process of This Article

Item

Count

Browse

318

Download

490

Sum=808

Mar 19, 2022 (publication date) through Apr 18, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Psychiatry. Mar 19, 2022; 12(3): 536-540
Published online Mar 19, 2022. doi: 10.5498/wjp.v12.i3.536

Table 1 Mendelian randomization analysis testing (A) severe, (B) hospitalized and (C) all COVID-19 forms against Alzheimer and anxiety risk in European ancestry

Disease	MR-Base ID	#IVs	P value	OR [95%CI]
(A)
AD	NA¹	8	0.193	1.006 [0.998; 1.014]
GAD	ukb-d-20544_15	5	0.090	1.006 [0.998; 1.014]
(B)
AD	NA¹	3	0.047	1.018 [1.000; 1.036]
GAD	ukb-d-20544_15	3	0.250	1.010 [0.994; 1.026]
(C)
AD	NA¹	10	0.169	1.014 [0.994; 1.034]
GAD	ukb-d-20544_15	5	0.580	1.006 [0.985; 1.028]

¹Not available on MR-Base (see Data Availability statement or [5] for details).

Odds ratios with 95% confidence intervals and P value from Mendelian randomization analyses are reported for each disorder tested as outcome against the three forms of coronavirus disease 2019 tested as exposure, with the number of instrumental variants (#IVs) analyzed. MR: Mendelian randomization; AD: Alzheimer’s disease; GAD: Generalized anxiety disorder; OR: Odds ratios; CI: Confidence interval; NA: Not available.

Citation: Tirozzi A, Santonastaso F, de Gaetano G, Iacoviello L, Gialluisi A. Does COVID-19 increase the risk of neuropsychiatric sequelae? Evidence from a mendelian randomization approach. World J Psychiatry 2022; 12(3): 536-540
URL: https://www.wjgnet.com/2220-3206/full/v12/i3/536.htm
DOI: https://dx.doi.org/10.5498/wjp.v12.i3.536